MAZE THERAPEUTICS, INC. COMMON STOCK

NASDAQ: MAZE (Maze Therapeutics, Inc.)

Last update: 6 hours ago

31.37

-1.06 (-3.27%)

Previous Close 32.43
Volume 818,930
Avg. Volume (3M) 737,145
Market Cap 1,715,416,576
Price / Sales 89.15
Price / Book 4.13
52 Weeks Range
21.95 (-30%) — 53.65 (71%)
Earnings Date 9 Nov 2026
Operating Margin (TTM) -820.82%
Diluted EPS (TTM) -2.62
Total Debt/Equity (MRQ) 13.92%
Current Ratio (MRQ) 14.14
Operating Cash Flow (TTM) -114.74 M
Levered Free Cash Flow (TTM) -68.62 M
Return on Assets (TTM) -21.98%
Return on Equity (TTM) -37.49%

AIStockmoo Score

0.9
Low debt. Weak profitability. Ample short-term liquidity. Negative cash flow. info
From our AI Insight report's view of expected return against risk. info NA
Relative Valuation info NA
Implied Growth info NA
Valuation History info NA
Return on Capital info NA
Holdings' Value info NA
Risk Premium info NA
Market Valuation info NA
No clear trend over the past year. Far below its 52-week high. info
In an uptrend: the price is above its moving averages, and they are rising. It is close to them. info
From our AI technical analysis of the chart. info NA
Candle Patterns info NA
No recent price targets, so based on how targets have been revised. info
Holdings' Sentiment info NA
News Mood info NA
Institutions net +15.00% of shares in their latest 13F filings: 90 holders increased, 65 decreased (quarter to 30 Sep 2026). info
Short interest +12.9% from 31 Aug to 30 Oct 2026, 8.8 days to cover (FINRA). info
Insider Activity info NA
Market environment cautious. info
Sector lagging the market.
The pillars agree, so the score is strengthened.
Earnings per share have risen every year. Made a loss in recent years. info
Above its medium-term trend line. info
Price is near its 52-week average. Up over 5 years. info
Trend up on all three terms. Short-term momentum fading. info
Price is near support. Levels trending down. info
Final Score 0.91
Show all

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Bullish
Biotechnology (Global) Mixed Bullish
Stock Maze Therapeutics, Inc. Mixed Bullish

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B Score
MAZE 2 B - - 4.13 0.9
PBLS 3 B - - 3.38 0.8
LEGN 3 B - - 2.59 -1.6
PVLA 2 B - - 10.82 0.9
IMCR 1 B - - 3.24 -0.2
GPCR 1 B - - 1.01 -0.8

Select this tab to load the latest available analysis.

Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.

Sector Healthcare
Industry Biotechnology
% Held by Insiders 1.55%
% Held by Institutions 111.81%

Ownership

Name Date Shares Held
Trv Gp Iv, Llc 30 Jun 2026 4,473,958

No data within this time range.

Institutions

Institutional ownership: 119.75%

Positions Holders Shares
Increased 90 10,413,211
Decreased 65 4,730,262
New 23 4,423,613
Sold out 24 1,859,070

SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.

Short Interest

Settlement Shares Days to cover
30 Oct 2026 6,684,604 8.8
15 Oct 2026 7,527,939 10.1
30 Sep 2026 6,565,330 6.1
15 Sep 2026 5,678,289 10.4
31 Aug 2026 5,918,321 16.0
14 Aug 2026 5,988,933 16.2

FINRA short interest via Nasdaq, reported twice a month.

1 Positive 0 Negative 2 Neutral
Date Type Details
09 Nov 2026 Yahoo Finance Maze Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
Enrollment completed in Phase 2 HORIZON trial of MZE829; data from all three cohorts expected in early 2027 Enrollment ongoing in Phase 2 CIPheR trial of MZE782 in PKU; topline data expected in 2027 Phase 2 trial of MZE782 in CKD on track for H1 2027 initiation Strong balance sheet with $477…
04 Nov 2026 Yahoo Finance Wall Street Analysts Predict a 93.92% Upside in Maze Therapeutics, Inc. (MAZE): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 93.9% in Maze Therapeutics, Inc. (MAZE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
03 Nov 2026 Yahoo Finance Maze Therapeutics to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D., chief executive…
19 Oct 2026 Yahoo Finance What Makes Maze Therapeutics, Inc. (MAZE) a New Buy Stock
Maze Therapeutics, Inc. (MAZE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
19 Oct 2026 Yahoo Finance Intel upgraded, PayPal downgraded: Wall Street's top analyst calls
Intel upgraded, PayPal downgraded: Wall Street's top analyst calls…
19 Oct 2026 Yahoo Finance How Much Upside is Left in Maze Therapeutics, Inc. (MAZE)? Wall Street Analysts Think 123.39%
The average of price targets set by Wall Street analysts indicates a potential upside of 123.4% in Maze Therapeutics, Inc. (MAZE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the…
13 Oct 2026 Yahoo Finance Pompe Disease Market Set for Expansion During the Forecast Period (2026-2036) as Growth is Fueled by Next-Generation ERTs, Newborn Screening, and Pipeline Innovation | DelveInsight
Recently published Pompe Disease Market Insights report includes a comprehensive understanding of current treatment practices, Pompe disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United…
06 Oct 2026 Yahoo Finance Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026
Oral presentation will highlight previously reported Phase 2 HORIZON data for MZE829 in patients with APOL1-mediated kidney disease Two poster presentations will highlight preclinical research supporting the therapeutic potential of SLC6A19 inhibition in chronic kidney disease SOUTH SAN FRANCISCO…
05 Oct 2026 Yahoo Finance 3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight
Small-cap stocks Ascentage Pharma, Maze Therapeutics, and Pagaya Technologies show improving fundamentals, strong cash positions, and bullish analyst ratings amid shifting investor interest.
28 Sep 2026 Yahoo Finance Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)?
On September 22, Truist analyst Danielle Brill identified a “significant positive readthrough” for Maze Therapeutics, Inc. (NASDAQ:MAZE) following positive Phase 2 topline data from Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). The data validates APOL1 inhibition in classic APOL1-mediated…
25 Sep 2026 Yahoo Finance Maze Therapeutics (MAZE) Shares Moved, So What Is Driving Attention Now?
Fresh Coverage Puts Maze Therapeutics in Focus Maze Therapeutics (MAZE) moved higher in pre-market trading on 23 September after CIBC began covering the clinical-stage kidney and metabolic disease specialist, with the share reaction unfolding alongside new kidney data from Vertex Pharmaceuticals.…
23 Sep 2026 Yahoo Finance Maze Therapeutics Shares Rise 2.9% After CIBC Initiates Coverage
Maze Therapeutics (NASDAQ:MAZE) shares rose 2. 9% in pre-market trading after CIBC initiated coverage of the clinical-stage biopharmaceutical company with an Outperformer rating and a $50 price target.
22 Sep 2026 Yahoo Finance The Surprise That Sent Vertex — And Its Chief Rival — Soaring
Vertex stock popped Tuesday — while shares of rival Maze Therapeutics skyrocketed — on a surprise expansion for their kidney disease drugs.
22 Sep 2026 Yahoo Finance Twin Moves: VRTX Rises On Kidney Disease Trial Results, MAZE Rallies Harder
Vertex on Tuesday announced results from the mid-stage trial of its experimental pill, inaxaplin, in two groups of patients with APOL1-mediated kidney disease.
22 Sep 2026 Yahoo Finance Vertex’s Kidney Drug Success Sparks a 22% Surge for This Rival Biotech
Maze Therapeutics stock jumped after Vertex Pharmaceuticals reported positive results for inaxaplin, boosting confidence in a rival treatment from Maze.
15 Sep 2026 Yahoo Finance SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development
Experienced biopharmaceutical and nephrology leader joins SCYNEXIS to advance its rare disease development programsJERSEY CITY, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (the Company or SCYNEXIS), a clinical-stage biotechnology company dedicated to advancing innovative…
11 Sep 2026 Yahoo Finance Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000
The executive liquidated his entire direct holdings as the stock plunged about 50% from its 52-week high.
02 Sep 2026 Yahoo Finance Maze Therapeutics to Participate in Three Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that company management will participate…
Show more

Recent Signals candle patterns and EMA crosses

▲ Golden cross 17 sessions ago · 28 Oct
Long term · EMA 50/200
The 50-day EMA crossed above the 200-day, a widely watched sign that the long-term trend has turned up.

Technical Setup Medium

Trend order
Slope
Entry
Volume
In an uptrend: the price is above its moving averages, and they are rising. It is close to them.
Nearest support: 29.69 – 31.72 · strong level
Nearest resistance: 32.14 – 33.99 · strong level

AI Technical Analysis

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Risk / Reward
TP1:
TP2:

Loss to SL against profit to each target, from EP. A ratio of 2 or more is usually sought.

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria